Table 2.
Analysis of factors associated with disease progression including baseline biomarker levels
| Variable | UVA |
MVA |
||||
|---|---|---|---|---|---|---|
| HR | 95% CI | p value | HR | 95% CI | p value | |
| Sex (female vs. male) | 0.94 | 0.55–1.62 | 0.832 | |||
| Tumor number (multiple vs. one) | 1.91 | 1.19–3.08 | 0.007 | 2.00 | 1.24–3.23 | 0.005 |
| Liver cirrhosis (yes vs. no) | 1.00 | 0.63–1.58 | 0.989 | |||
| Child-pugh class (B vs. A) | 1.40 | 0.70–2.83 | 0.345 | |||
| Concurrent chemotherapy (no vs. yes) | 0.99 | 0.62–1.62 | 0.989 | |||
| PVTT (yes vs. no) | 1.33 | 0.84–2.10 | 0.225 | |||
| Previous treatment (yes vs. no) | 1.34 | 0.85–2.12 | 0.207 | 1.99 | 1.16–3.42 | 0.013 |
| Age (>60 vs. ≤60) | 1.01 | 0.64–1.60 | 0.953 | |||
| Tumor size (>6.5 cm vs. ≤6.5 cm) | 1.01 | 0.64–1.60 | 0.964 | |||
| Lymph node metastasis (yes vs. no) | 0.95 | 0.41–2.19 | 0.896 | |||
| Treatment aim (salvage vs. definitive) | 1.15 | 0.73–1.82 | 0.551 | |||
| UICC stage | 0.088 | |||||
| III versus II | 1.66 | 0.91–3.04 | 0.100 | |||
| IV versus II | 1.92 | 1.07–3.46 | 0.030 | |||
| AFP (>71.13 ng/mL vs. ≤71.13 ng/mL) | 1.41 | 0.89–2.22 | 0.146 | |||
| PIVKA-II (>1,629 mAU/mL vs. ≤1,629 mAU/mL) | 1.35 | 0.85–2.13 | 0.207 | 1.79 | 1.04–3.09 | 0.036 |
| sPD-L1 (pg/mL) | 1.01 | 1.00–1.03 | 0.044 | 1.02 | 1.00–1.03 | 0.041 |
| IFN-γ (pg/mL) | 1.00 | 0.90–1.11 | 0.991 | |||
| IL-6 (pg/mL) | 1.00 | 0.99–1.01 | 0.744 | |||
| IL-10 (pg/mL) | 1.08 | 0.96–1.22 | 0.189 | |||
| ITIH4 (ng/mL) | 1.00 | 1.00–1.00 | 0.194 | |||
| cfDNA (ug/mL) | 1.03 | 1.00–1.06 | 0.074 | |||
PVTT, portal vein tumor thrombosis; UICC, Union for International Cancer Control.